Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Pancreatic and Hepatobiliary Cancers

ASCO Direct Highlights™ Miami 2021 Symposium

9 - 10 Jul 2021

Published: 28 Jul 2021

Views: 836

Rating:

Save

Dr Caio Max Rocha Lima - Wake Forest Baptist Health, North Carolina, USA

Dr Caio Max Rocha Lima speaks to ecancer about a study carried out by the Dutch group to investigate the neoadjuvant use of gemcitabine for pancreatic and hepatobiliary cancer.

Initially, he explains the background and methodology of the study. Dr Lima then discusses the results of this study.

To conclude, he mentions the impact these results can have on the future treatment of pancreatic and hepatobiliary cancer.

Watch the meeting in full by following the links below:

Related Videos

Avelumab plus platinum-based chemotherapy may show some efficacy in patients...

Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece

Avelumab plus platinum-based chemotherapy may show some efficacy in patients with extensive-stage small cell lung cancer ( Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece )

Addition of atezolizumab to chemotherapy after surgery does not improve...

Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA

Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer ( Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA )

Comment: EBCC 2024 highlights

Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) andDr...

Comment: EBCC 2024 highlights ( Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) andDr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium) )

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic...

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City...

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell...

Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy ( Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA )

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable...

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )

Perioperative nivolumab did not improve RFS in RCC patients at high risk for...

Dr Mohamad Allaf - The Johns Hopkins Hospital, Baltimore, USA

Perioperative nivolumab did not improve RFS in RCC patients at high risk for recurrence ( Dr Mohamad Allaf - The Johns Hopkins Hospital, Baltimore, USA )

More from ecancer